Actively Recruiting
Lateral Femoral Cutaneous Nerve Block or Wound Infiltration Combined With Pericapsular Nerve Group Block for Analgesia in Elective Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial
Led by Ospedale Edoardo Bassini · Updated on 2026-03-25
102
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are comparing two regional anesthesia methods to manage pain after elective total hip arthroplasty (THA) performed via the anterior approach. This randomized controlled trial evaluates the use of a Pericapsular Nerve Group (PENG) block combined either with a Lateral Femoral Cutaneous Nerve (LFCN) block or with wound infiltration (WI) to find which method better controls postoperative pain. The study focuses on pain intensity at rest six hours after surgery and also looks at other factors like opioid use and mobility. Participants will be randomly assigned to one of two groups. One group receives a PENG block with an LFCN block under ultrasound guidance, using 20 ml and 10 ml of 0.5% ropivacaine respectively, following neuraxial anesthesia. The other group receives a PENG block with 20 ml of 0.5% ropivacaine and a wound infiltration of 10 ml 0.5% ropivacaine after surgery. Both procedures are standard clinical practices with minimal additional risk. During the study, participants will be assessed for pain at rest and during movement at 6, 24, and 48 hours after regional anesthesia. Researchers will also measure opioid consumption, time to first rescue pain medication, muscle strength, hip flexion, length of hospital stay, and any complications. Safety is closely monitored throughout. Participation involves regular evaluations up to 48 hours post-surgery and observation of hospital stay length, with study activities concluding by November 2026.
CONDITIONS
Brief Title
Pericapsular Nerve Group (PENG) Block Combined With Lateral Femoral Cutaneous Nerve (LFCN) Block or Wound Infiltration for Postoperative Analgesia in Anterior Approach Total Hip Arthroplasty: A Randomized Controlled Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Elective total hip arthroplasty
- Spinal (subarachnoid) anesthesia
- Written informed consent provided by the patient or legal guardian if appointed
You will not qualify if you...
- INR > 1.5
- aPTT > 1.5
- Platelet count < 75,000/mm³
- Signs suggestive of infection at the puncture site
- Absence of informed consent to the procedure
- Documented or suspected allergy to local anesthetics
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of surgery
Participants undergo anterior approach total hip arthroplasty under spinal anesthesia. They receive either a combination of pericapsular nerve group (PENG) block with lateral femoral cutaneous nerve (LFCN) block or PENG block with wound infiltration for postoperative pain management.
1 surgical visit (in-person)
Duration - Up to 48 hours after surgery
Participants are monitored for pain control, hip flexion, opioid use, and complications in the 48 hours following surgery.
Visits during the first 48 hours post-surgery
Duration - Up to 10 months
Participants' length of hospital stay and recovery progress are followed up to 10 months after surgery.
Follow-up visits as per routine care
Trial Site Locations
Total: 1 location
1
Ospedale Edoardo Bassini
Cinisello Balsamo, Milano, Italy, 20092
Actively Recruiting
Research Team
M
Matteo Coccolo, MD
A
Angelo Pezzi, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here